Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
desktop iconMarkt Monitor

Aandeel Pharming Group AEX:PHARM.NL, NL0010391025

Laatste koers (eur) Verschil Volume
0,810   0,000   (0,00%) Dagrange 0,778 - 0,818 11.186.090   Gem. (3M) 3,9M

Pharming woensdag 19 feb

946 Posts
Pagina: «« 1 ... 42 43 44 45 46 ... 48 »» | Laatste | Omlaag ↓
  1. [verwijderd] 19 februari 2014 17:43
    Invitation - Presentation of Sobi's fourth quarter and full year results 2013
    2014-02-10
    On 20 February, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobi) will publish its report for the fourth quarter and full year, 2013.

    Financial analysts and media are invited to participate in a telephone conference, which will include a presentation of the results, at 14:00 CET. The event will be hosted by Sobi's CEO and President, Geoffrey McDonough. The presentation will be held in English.

    The presentation can be followed live, or afterwards on www.sobi.com. Slides used in the presentation will be made available on our website prior to the telephone conference.

    To participate in the telephone conference, please call:
    SE: +46 8 5199 9350
    UK: +44 203 364 5372
    US: +1 877 788 9023

    Audience URL: event.onlineseminarsolutions.com/r.ht...

    ---

    About Sobi
    Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on inflammation and genetic diseases, with three late stage biological development projects within haemophilia and neonatology. We also market a portfolio of specialty and rare disease products for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2012, Sobi had total revenues of SEK 1.9 billion (€ 215 M) and about 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com.

    For more information - not for publication

    Media relations Investor relations
    Oskar Bosson, Head of Communications Jörgen Winroth, Vice President, Head of Investor Relations
    T: +46 70 410 71 80 T: +46 8 697 20 00
    oskar.bosson@sobi.com jorgen.winroth@sobi.com
  2. [verwijderd] 19 februari 2014 17:44
    quote:

    Ulrock schreef op 19 februari 2014 17:34:

    ik vandaag ook achterlijk ver en ingekocht.. net nog ingekocht omdat het sterke einde ergens in mijn gedachten morgen voor een hoge opening zullen zorgen..

    had nou gewoon niet verkocht met hoop op de 62 lol :) u had het nog zo beloofd, niet verkopen voor de 1 euro.
  3. forum rang 10 voda 19 februari 2014 17:53
    quote:

    tepper schreef op 19 februari 2014 17:41:

    Hoogste slotkoers van de afgelopen jaren: € 0,668
    PS:

    De hoogste intradag koers: (72.6 cent)

    Fonds: aand. Pharming Group
    Beurs: Euronext Amsterdam

    Laatste Volume Tijd
    Laatste 0,631 2.500 17:38:50
    Verschil -0,022 -3,3691 %
    Bied 0,624 110.000 17:38:26
    Laat 0,631 31.063 17:38:50
    Hoogste 0,726 09:14:28
    Laagste 0,611 17:27:28
    Cum. volume --- 134.109.379 17:38:50
    Indicatieve opening ---
    Open 0,66 09:00:02
    Vorig slot 0,653 17-02-2014
    Gemiddelde dagomzet --- 24.643.839
946 Posts
Pagina: «« 1 ... 42 43 44 45 46 ... 48 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.